Recovery of function requires the regeneration and rewiring of neurons. The major factors limiting regrowth are extracellular inhibitors in CNS tissue called Nogo-A, MAG and OMgp. The company has developed a decoy receptor – called Nogo Trap - that binds the growth inhibitors allowing the body to grow nerve fibers naturally and directly targeting restoration across all facets of growth: axonal regeneration (long distance), axonal sprouting (medium distance) and synaptic plasticity.
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth. The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.
Manufacturing/Regulatory -The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1 safety trial in patients with chronic spinal cord injury.
Patents- The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use .
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth. The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.
Manufacturing/Regulatory -The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1 safety trial in patients with chronic spinal cord injury.
Patents- The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use .